| Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA DM Kurtz, J Soo, L Co Ting Keh, S Alig, JJ Chabon, BJ Sworder, A Schultz, ... Nature biotechnology 39 (12), 1537-1547, 2021 | 179 | 2021 |
| Inferring gene expression from cell-free DNA fragmentation profiles MS Esfahani, EG Hamilton, M Mehrmohamadi, BY Nabet, SK Alig, ... Nature biotechnology 40 (4), 585-597, 2022 | 78 | 2022 |
| Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas BJ Sworder, DM Kurtz, SK Alig, MJ Frank, N Shukla, A Garofalo, ... Cancer Cell 41 (1), 210-225. e5, 2023 | 51 | 2023 |
| Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma S Alig, CW Macaulay, DM Kurtz, U Dührsen, A Hüttmann, C Schmitz, ... Journal of Clinical Oncology 39 (23), 2605-2616, 2021 | 43 | 2021 |
| CD58 aberrations limit durable responses to CD19 CAR in large B cell lymphoma patients treated with axicabtagene ciloleucel but can be overcome through novel CAR engineering RG Majzner, MJ Frank, C Mount, A Tousley, DM Kurtz, B Sworder, ... Blood 136, 53-54, 2020 | 43 | 2020 |
| Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas JA Mutter, SK Alig, MS Esfahani, EM Lauer, J Mitschke, DM Kurtz, J Kühn, ... Journal of Clinical Oncology 41 (9), 1684-1694, 2023 | 39 | 2023 |
| Follicular dendritic cells modulate germinal center B cell diversity through FcγRIIB CE van der Poel, G Bajic, CW Macaulay, T van den Broek, CD Ellson, ... Cell reports 29 (9), 2745-2755. e4, 2019 | 37 | 2019 |
| Circulating DNA for molecular response prediction, characterization of resistance mechanisms and quantification of CAR T-cells during axicabtagene ciloleucel therapy B Sworder, DM Kurtz, C Macaulay, MJ Frank, S Alig, A Garofalo, B Sahaf, ... Blood 134, 550, 2019 | 18 | 2019 |
| Profiling of circulating tumor DNA for noninvasive disease detection, risk stratification, and MRD monitoring in patients with CNS lymphoma JA Mutter, S Alig, EM Lauer, MS Esfahani, J Mitschke, DM Kurtz, J Kühn, ... Blood 138 (Supplement 1), 6-6, 2021 | 17 | 2021 |
| Towards non-invasive classification of DLBCL genetic subtypes by Ctdna profiling MS Esfahani, S Alig, DM Kurtz, J Soo, MC Jin, C Macaulay, AFM Craig, ... Blood 134, 551, 2019 | 9 | 2019 |
| MRD-negativity as a potential surrogate endpoint after frontline DLBCL therapy: pooled analysis of trials & implications for clinical trial design M Roschewski, DM Kurtz, J Westin, RC Lynch, C Macaulay, C Kuffer, ... Blood 140 (Supplement 1), 785-786, 2022 | 6 | 2022 |
| Phased variant enrichment for enhanced minimal residual disease detection from cell-free DNA DM Kurtz, J Soo, S Alig, LCT Keh, C Macaulay, MC Jin, F Scherer, ... Blood 134, 552, 2019 | 6 | 2019 |
| A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL HJJ Cherng, SK Alig, Y Oki, LJ Nastoupil, L Fayad, SS Neelapu, ... Blood Advances 7 (7), 1137-1145, 2023 | 5 | 2023 |
| MATRIX INDUCTION FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT OR WHOLE‐BRAIN IRRADIATION IN PRIMARY CNS LYMPHOMA. 7‐YEAR RESULTS OF THE IELSG32 RANDOMIZED TRIAL JA Mutter, S Alig, EM Lauer, MS Esfahani, J Mitschke, DM Kurtz, M Olsen, ... Hematological Oncology 39, 2021 | 5 | 2021 |
| Interim circulating tumor DNA as a prognostic biomarker in the setting of interim PET-based adaptive therapy for DLBCL C Macaulay, S Alig, DM Kurtz, MC Jin, S Opat, J Soo, B Sworder, ... Blood 134, 1600, 2019 | 5 | 2019 |
| MRD‐negativity after frontline DLBCL therapy: pooled analysis of 6 clinical trials M Roschewski, DM Kurtz, J Westin, RC Lynch, SK Alig, C Macaulay, ... Hematological Oncology 41, 177-179, 2023 | 3 | 2023 |
| Profiling T-cell receptor diversity and dynamics during lymphoma immunotherapy using cell-free DNA (cfDNA) ND Shukla, AFM Craig, B Sworder, DM Kurtz, C Macaulay, A Garofalo, ... Blood 136, 49-50, 2020 | 3 | 2020 |
| Noninvasive detection, classification, and risk stratification of primary CNS lymphomas by CTDNA profiling JA Mutter, S Alig, EM Lauer, MS Esfahani, J Mitschke, DM Kurtz, M Olsen, ... Hematological Oncology 39, 2021 | 2 | 2021 |
| Noninvasive genotyping and monitoring of classical Hodgkin lymphoma MC Jin, JG Schroers-Martin, DM Kurtz, L Buedts, MS Esfahani, ... Blood 132, 2838, 2018 | 2 | 2018 |
| Short diagnosis-to-treatment interval is associated with higher levels of circulating tumor DNA in aggressive B-cell non-Hodgkin lymphoma S Alig, C Macaulay, DM Kurtz, U Dührsen, A Hüttmann, MC Jin, ... Blood 134, 491, 2019 | 1 | 2019 |
